Biosimilar competitors shouldn’t be persistently related to decrease out-of-pocket (OOP) prices for commercially insured outpatients, in accordance with a research printed on-line March 29 in JAMA Well being Discussion board.
Kimberly Feng, M.D., from Brigham and Girls’s Hospital in Boston, and colleagues investigated whether or not biosimilar competitors is related to decrease OOP spending for sufferers utilizing biologics. The evaluation included nationwide claims information (Optum Clinformatics Knowledge Mart) for 190,364 people (youthful than 65 years of age) with outpatient claims for one in all seven clinician-administered biologics (filgrastim, infliximab, pegfilgrastim, epoetin alfa, bevacizumab, rituximab, and trastuzumab) from January 2009 by way of March 2022.
The researchers discovered that annual OOP prices elevated earlier than and after biosimilar availability. In contrast with the yr earlier than biosimilar competitors, two years after the beginning of biosimilar competitors, the adjusted odds ratio of nonzero annual OOP spending was 1.08 and common nonzero annual spending was 12 % larger. Claims for biosimilars had been extra probably than reference biologics to have nonzero OOP prices (adjusted odds ratio, 1.13) however had decrease imply nonzero OOP prices (adjusted imply ratio, 0.92). There was variance by drug.
“Findings of this research counsel that the introduction of biosimilar competitors didn’t systematically decrease affected person OOP spending on biologics, highlighting the necessity for focused coverage interventions to make sure that financial savings from biosimilar competitors improves affordability for sufferers,” the authors write.
Extra info:
Kimberly Feng et al, Affected person Out-of-Pocket Prices for Biologic Medication After Biosimilar Competitors, JAMA Well being Discussion board (2024). DOI: 10.1001/jamahealthforum.2023.5429
Andrew W. Mulcahy, Revisiting Expectations of US Biosimilars—Panacea or One Piece of the Puzzle?, JAMA Well being Discussion board (2024). DOI: 10.1001/jamahealthforum.2023.4778
Copyright © 2024 HealthDay. All rights reserved.
Quotation:
Biosimilar biologics don’t at all times cut back out-of-pocket prices (2024, April 2)
retrieved 2 April 2024
from
This doc is topic to copyright. Other than any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.